newsfilter
← Earnings
Earnings Releases·

Lexicon Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Total revenues decreased to $11.3 million in Q3 2026 from $14.2 million in Q3 2025, driven by a shift from licensing revenue to $10.0 million in development milestones and $1.2 million in INPEFA net sales.
  • Net loss widened to $14.0 million ($0.03 per share) in Q3 2026 compared to $12.8 million ($0.04 per share) in Q3 2025, while R&D expenses fell to $16.2 million due to completed Phase 2b trials, partially offset by increased SG&A to $9.5 million.
  • Key clinical milestones include the completion of SONATA-HCM Phase 3 enrollment with top-line data expected in Q1 2027, positive STENO1 safety data supporting a Q1 2027 NDA resubmission for ZYNQUISTA, and a third $10 million milestone from Novo for LX9851.
  • Liquidity strengthened with cash, investments, and restricted cash rising to $183.2 million as of September 30, 2026, from $125.2 million at year-end 2025, primarily due to $96.2 million in equity proceeds, while long-term debt increased to $51.9 million.
Company
LEXICON PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology